These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature. Ngo D; Patel S; Kim EJ; Brar R; Koontz MZ J Oncol Pharm Pract; 2015 Aug; 21(4):296-300. PubMed ID: 24664478 [TBL] [Abstract][Full Text] [Related]
6. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group. Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663 [TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Hijiya N; Thomson B; Isakoff MS; Silverman LB; Steinherz PG; Borowitz MJ; Kadota R; Cooper T; Shen V; Dahl G; Thottassery JV; Jeha S; Maloney K; Paul JA; Barry E; Carroll WL; Gaynon PS Blood; 2011 Dec; 118(23):6043-9. PubMed ID: 21967976 [TBL] [Abstract][Full Text] [Related]
9. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360 [TBL] [Abstract][Full Text] [Related]
10. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma. Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266 [TBL] [Abstract][Full Text] [Related]
11. Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma. Lalayanni C; Baldoumi E; Papayiannopoulos S; Tziola K; Saloum R; Anagnostopoulos A Curr Probl Cancer; 2017; 41(2):138-143. PubMed ID: 28169005 [TBL] [Abstract][Full Text] [Related]
12. Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia. Messinger Y; Boklan J; Goldberg J; DuBois SG; Oesterheld J; Abla O; Martin A; Weinstein J; Hijiya N Pediatr Hematol Oncol; 2017 May; 34(4):187-198. PubMed ID: 29039989 [TBL] [Abstract][Full Text] [Related]
13. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. Candoni A; Lazzarotto D; Ferrara F; Curti A; Lussana F; Papayannidis C; Del Principe MI; Bonifacio M; Mosna F; Delia M; Minetto P; Gottardi M; Fracchiolla N; Mancini V; Forghieri F; Zappasodi P; Cerrano M; Vitale A; Audisio E; Trappolini S; Romani C; Defina M; Imbergamo S; Ciccone N; Santoro L; Cambò B; Iaccarino S; Dargenio M; Aprile L; Chiaretti S; Fanin R; Pizzolo G; Foà R Am J Hematol; 2020 Dec; 95(12):1466-1472. PubMed ID: 32777149 [TBL] [Abstract][Full Text] [Related]
14. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Boddu PC; Senapati J; Ravandi-Kashani F; Jabbour EJ; Jain N; Ayres M; Chen Y; Keating MJ; Kantarjian HM; Gandhi V; Kadia TM Cancer; 2023 Feb; 129(4):580-589. PubMed ID: 36448227 [TBL] [Abstract][Full Text] [Related]
15. Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma. Yanagi M; Mori M; Honda M; Mitani Y; Seki M; Fukuoka K; Oshima K; Arakawa Y; Koh K Int J Hematol; 2024 Mar; 119(3):327-333. PubMed ID: 38302839 [TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study. Kazama H; Nishina S; Seto T Jpn J Clin Oncol; 2024 Jul; 54(7):778-786. PubMed ID: 38643356 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL. Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993 [TBL] [Abstract][Full Text] [Related]
18. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Kadia TM; Gandhi V Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523 [TBL] [Abstract][Full Text] [Related]
19. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. DeAngelo DJ Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456 [TBL] [Abstract][Full Text] [Related]
20. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. Kurtzberg J; Ernst TJ; Keating MJ; Gandhi V; Hodge JP; Kisor DF; Lager JJ; Stephens C; Levin J; Krenitsky T; Elion G; Mitchell BS J Clin Oncol; 2005 May; 23(15):3396-403. PubMed ID: 15908652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]